Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma

Y. Matsui, A. Figi, M. Horikawa, Y. Jahangiri Noudeh, Y. Tomozawa, K. Hashimoto, John Kaufman, Khashayar Farsad

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives The purpose of this study was to investigate the incidence of and the risk factors for arteriopathy in hepatic arteries after transarterial chemo-lipiodolization in patients with hepatocellular carcinoma and the subsequent treatment strategy changes due to arteriopathy. Patients and methods A total of 365 arteries in 167 patients (126 men and 41 women; mean age, 60.4 ± 15.0 [SD] years [range: 18–87 years]) were evaluated for the development of arteriopathy after chemo-lipiodolization with epirubicin- or doxorubicin-Lipiodol® emulsion. The development of arteriopathy after chemo-lipiodolization was assessed on arteriograms performed during subsequent transarterial treatments. The treatment strategy changes due to arteriopathy, including change in the chemo-lipiodolization method and the application of alternative therapies was also investigated. Univariate and multivariate binary logistic regression models were used to identify risk factors for arteriopathy and subsequent treatment strategy change. Results One hundred two (27.9%) arteriopathies were detected in 62/167 (37.1%) patients (45 men, 17 women) with a mean age of 63.3 ± 7.1 [SD] years (age range, 50–86 years). The incidence of arteriopathy was highly patient dependent, demonstrating significant correlation in a fully-adjusted multivariate regression model (P < 0.0001). Multivariate-adjusted regression analysis with adjustment for the patient effect showed a statistically significant association of super-selective chemo-lipiodolization (P = 0.003) with the incidence of arteriopathy. Thirty of the 102 arteriopathies (29.4%) caused a change in treatment strategy. No factors were found to be significantly associated with the treatment strategy change. Conclusion The incidence of arteriopathy after chemo-lipiodolization is 27.9%. Among them, 29.4% result in a change in treatment strategy.

Original languageEnglish (US)
Pages (from-to)827-835
Number of pages9
JournalDiagnostic and interventional imaging
Volume98
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Hepatocellular Carcinoma
Incidence
Therapeutics
Logistic Models
Ethiodized Oil
Epirubicin
Hepatic Artery
Complementary Therapies
Emulsions
Doxorubicin
Arteries
Regression Analysis

Keywords

  • Arteriopathy
  • Chemo-lipiodolization
  • Hepatocellular carcinoma
  • Intra-arterial chemotherapy
  • Lipiodol (ethiodized oil)

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. / Matsui, Y.; Figi, A.; Horikawa, M.; Jahangiri Noudeh, Y.; Tomozawa, Y.; Hashimoto, K.; Kaufman, John; Farsad, Khashayar.

In: Diagnostic and interventional imaging, Vol. 98, No. 12, 01.12.2017, p. 827-835.

Research output: Contribution to journalArticle

Matsui Y, Figi A, Horikawa M, Jahangiri Noudeh Y, Tomozawa Y, Hashimoto K et al. Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. Diagnostic and interventional imaging. 2017 Dec 1;98(12):827-835. https://doi.org/10.1016/j.diii.2017.10.010
Matsui, Y. ; Figi, A. ; Horikawa, M. ; Jahangiri Noudeh, Y. ; Tomozawa, Y. ; Hashimoto, K. ; Kaufman, John ; Farsad, Khashayar. / Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. In: Diagnostic and interventional imaging. 2017 ; Vol. 98, No. 12. pp. 827-835.
@article{7ecbb882ee804a8d93e84e404852a5d2,
title = "Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma",
abstract = "Objectives The purpose of this study was to investigate the incidence of and the risk factors for arteriopathy in hepatic arteries after transarterial chemo-lipiodolization in patients with hepatocellular carcinoma and the subsequent treatment strategy changes due to arteriopathy. Patients and methods A total of 365 arteries in 167 patients (126 men and 41 women; mean age, 60.4 ± 15.0 [SD] years [range: 18–87 years]) were evaluated for the development of arteriopathy after chemo-lipiodolization with epirubicin- or doxorubicin-Lipiodol{\circledR} emulsion. The development of arteriopathy after chemo-lipiodolization was assessed on arteriograms performed during subsequent transarterial treatments. The treatment strategy changes due to arteriopathy, including change in the chemo-lipiodolization method and the application of alternative therapies was also investigated. Univariate and multivariate binary logistic regression models were used to identify risk factors for arteriopathy and subsequent treatment strategy change. Results One hundred two (27.9{\%}) arteriopathies were detected in 62/167 (37.1{\%}) patients (45 men, 17 women) with a mean age of 63.3 ± 7.1 [SD] years (age range, 50–86 years). The incidence of arteriopathy was highly patient dependent, demonstrating significant correlation in a fully-adjusted multivariate regression model (P < 0.0001). Multivariate-adjusted regression analysis with adjustment for the patient effect showed a statistically significant association of super-selective chemo-lipiodolization (P = 0.003) with the incidence of arteriopathy. Thirty of the 102 arteriopathies (29.4{\%}) caused a change in treatment strategy. No factors were found to be significantly associated with the treatment strategy change. Conclusion The incidence of arteriopathy after chemo-lipiodolization is 27.9{\%}. Among them, 29.4{\%} result in a change in treatment strategy.",
keywords = "Arteriopathy, Chemo-lipiodolization, Hepatocellular carcinoma, Intra-arterial chemotherapy, Lipiodol (ethiodized oil)",
author = "Y. Matsui and A. Figi and M. Horikawa and {Jahangiri Noudeh}, Y. and Y. Tomozawa and K. Hashimoto and John Kaufman and Khashayar Farsad",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.diii.2017.10.010",
language = "English (US)",
volume = "98",
pages = "827--835",
journal = "Diagnostic and interventional imaging",
issn = "2211-5684",
publisher = "Elsevier Masson",
number = "12",

}

TY - JOUR

T1 - Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma

AU - Matsui, Y.

AU - Figi, A.

AU - Horikawa, M.

AU - Jahangiri Noudeh, Y.

AU - Tomozawa, Y.

AU - Hashimoto, K.

AU - Kaufman, John

AU - Farsad, Khashayar

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Objectives The purpose of this study was to investigate the incidence of and the risk factors for arteriopathy in hepatic arteries after transarterial chemo-lipiodolization in patients with hepatocellular carcinoma and the subsequent treatment strategy changes due to arteriopathy. Patients and methods A total of 365 arteries in 167 patients (126 men and 41 women; mean age, 60.4 ± 15.0 [SD] years [range: 18–87 years]) were evaluated for the development of arteriopathy after chemo-lipiodolization with epirubicin- or doxorubicin-Lipiodol® emulsion. The development of arteriopathy after chemo-lipiodolization was assessed on arteriograms performed during subsequent transarterial treatments. The treatment strategy changes due to arteriopathy, including change in the chemo-lipiodolization method and the application of alternative therapies was also investigated. Univariate and multivariate binary logistic regression models were used to identify risk factors for arteriopathy and subsequent treatment strategy change. Results One hundred two (27.9%) arteriopathies were detected in 62/167 (37.1%) patients (45 men, 17 women) with a mean age of 63.3 ± 7.1 [SD] years (age range, 50–86 years). The incidence of arteriopathy was highly patient dependent, demonstrating significant correlation in a fully-adjusted multivariate regression model (P < 0.0001). Multivariate-adjusted regression analysis with adjustment for the patient effect showed a statistically significant association of super-selective chemo-lipiodolization (P = 0.003) with the incidence of arteriopathy. Thirty of the 102 arteriopathies (29.4%) caused a change in treatment strategy. No factors were found to be significantly associated with the treatment strategy change. Conclusion The incidence of arteriopathy after chemo-lipiodolization is 27.9%. Among them, 29.4% result in a change in treatment strategy.

AB - Objectives The purpose of this study was to investigate the incidence of and the risk factors for arteriopathy in hepatic arteries after transarterial chemo-lipiodolization in patients with hepatocellular carcinoma and the subsequent treatment strategy changes due to arteriopathy. Patients and methods A total of 365 arteries in 167 patients (126 men and 41 women; mean age, 60.4 ± 15.0 [SD] years [range: 18–87 years]) were evaluated for the development of arteriopathy after chemo-lipiodolization with epirubicin- or doxorubicin-Lipiodol® emulsion. The development of arteriopathy after chemo-lipiodolization was assessed on arteriograms performed during subsequent transarterial treatments. The treatment strategy changes due to arteriopathy, including change in the chemo-lipiodolization method and the application of alternative therapies was also investigated. Univariate and multivariate binary logistic regression models were used to identify risk factors for arteriopathy and subsequent treatment strategy change. Results One hundred two (27.9%) arteriopathies were detected in 62/167 (37.1%) patients (45 men, 17 women) with a mean age of 63.3 ± 7.1 [SD] years (age range, 50–86 years). The incidence of arteriopathy was highly patient dependent, demonstrating significant correlation in a fully-adjusted multivariate regression model (P < 0.0001). Multivariate-adjusted regression analysis with adjustment for the patient effect showed a statistically significant association of super-selective chemo-lipiodolization (P = 0.003) with the incidence of arteriopathy. Thirty of the 102 arteriopathies (29.4%) caused a change in treatment strategy. No factors were found to be significantly associated with the treatment strategy change. Conclusion The incidence of arteriopathy after chemo-lipiodolization is 27.9%. Among them, 29.4% result in a change in treatment strategy.

KW - Arteriopathy

KW - Chemo-lipiodolization

KW - Hepatocellular carcinoma

KW - Intra-arterial chemotherapy

KW - Lipiodol (ethiodized oil)

UR - http://www.scopus.com/inward/record.url?scp=85037653255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037653255&partnerID=8YFLogxK

U2 - 10.1016/j.diii.2017.10.010

DO - 10.1016/j.diii.2017.10.010

M3 - Article

C2 - 29157897

AN - SCOPUS:85037653255

VL - 98

SP - 827

EP - 835

JO - Diagnostic and interventional imaging

JF - Diagnostic and interventional imaging

SN - 2211-5684

IS - 12

ER -